Monopar CEO RSUs vest; shares withheld for tax
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported compensation-related stock activity.
Rhea-AI Filing Summary
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported compensation-related stock activity. On June 30, 2026, 12,873 restricted stock units vested and settled into the same number of common shares. The issuer withheld 4,084 shares at $92.59 per share to cover applicable tax obligations.
Following these transactions, Robinson holds 99,267 shares of Monopar common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. The filing reflects routine RSU vesting and associated tax-withholding dispositions, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 12,873 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,873 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 4,084 | $92.59 | $378K |
| holding | Common Stock | -- | -- | -- |
Footnotes (6)
- F1. Represents shares acquired on vesting and settlement of restricted stock units.
- F2. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- F3. Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
- F4. On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- F5. On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- F6. On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Key Figures
Key Terms
Restricted stock units financial
tax-withholding disposition financial
derivative security financial
Irrevocable Trust financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Monopar Therapeutics (MNPR) report for its CEO?
What do the Monopar (MNPR) RSU grants in the footnotes indicate?
Is the Monopar (MNPR) CEO’s Form 4 a buy or sell signal?
AI-generated analysis. How Rhea-AI works. Not financial advice.